Page 39 - Gates-AnnualReport-2018

(SOM) in connection with a trial at UCHealth. This project is a collaboration with the SOM Clinical Research Administration Office (CRAO), SOM Division of Hematology and the UCHealth Bone Marrow Transplant Clinic. This clinical trial will pave the way for many university-sponsored clinical trials in the future. With the help of our Medical Director, Roger Giller M.D., we are also in the process of establishing procedures for providing a similar product for patients at Children’s Hospital Colorado. Dr. Terry Fry, Director of Cancer Immunotherapy, described the unique nature of this campus-wide coordination, stating that “It certainly facilitates cross fertilization and collaboration when you have adult and children’s hospital research programs and a GMP facility all on one campus. That’s sort of an unbelievable opportunity.”
After a few iterations, the GBF finalized its governance structure with the first meeting of the Gates Biomanufacturing Advisory Board in June 2018. The Advisory Board consists of the Chancellor of the Anschutz Medical Campus, the Dean of the School of Medicine, leadership from our funding partners—UC Health, Children’s Hospital Colorado, and the Gates Frontiers Fund, along with other campus staff and volunteers with expertise in GMP manufacturing and clinical
trial operations. We also have a Finance Advisory Committee in place consisting of the Chief Financial Officers of the Anschutz Chancellor’s office, School of Medicine, UCHealth and Children’s Hospital Colorado. This new structure provides a clear decision-making process that allows us to evaluate risks and make appropriate operating and financial decisions in a timely manner. This governance structure distinguishes us from most other universities run by combinations of committees, andprovidesacompetitiveadvantageforourclients.
It has taken considerable financial resources to build the facility, hire and retain the talented team, and maintain the quality system and the equipment used for operations. Our funding partners have been unwavering in their commitment to quality and their financial support of the facility. None of our success to date would have been possible without this ongoing support.
Looking forward, we are in a great position to achieve our mission, which is “to accelerate the translation of scientific discoveries into human clinical trials as safely, efficiently, and cost effectively as possible according to high quality standards.”
Protein Suite
Cell Therapy
Gates Center for Regenerative Medicine 39